FIELD: pharmaceutical chemistry.
SUBSTANCE: invention relates, in particular, to a composition for interaction of ligands wherein the composition comprises a noncovalent associate of multiple separate conjugates being each of that comprises a head group and a tail group wherein tail groups of conjugates form hydrophobic aggregate. Conjugates are mobile within the associate and in the presence of ligand at least two head groups are places by a method corresponding to the epitope formation that is able to interact with ligand stronger as compared with each separate head group. Invention provides applying conjugates in combinatory approach for detecting effective combinations to induce the desirable interaction in binding in receptor-specific treatment of patients.
EFFECT: valuable properties of epitopes.
31 cl, 2 dwg, 4 ex
Title | Year | Author | Number |
---|---|---|---|
PEPTIDES | 2007 |
|
RU2496789C2 |
VACCINE COMPOSITION AND USE THEREOF | 2016 |
|
RU2726411C2 |
BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | 2015 |
|
RU2708459C2 |
DRUG BILIGAND CONJUGATE AND USE THEREOF | 2020 |
|
RU2820346C2 |
FUSED DRUG CONSTRUCTS AND CONJUGATES | 2005 |
|
RU2428431C2 |
BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | 2015 |
|
RU2824959C2 |
RGD-CONTAINING PEPTIDOMIMETICS AND THEIR APPLICATION | 2009 |
|
RU2519736C2 |
RECOMBINANT PROTEINS AND THEIR THERAPEUTIC USES | 2012 |
|
RU2650574C2 |
ANTIBODY TO AMYLOID BETA | 2013 |
|
RU2651486C2 |
NOVEL POLYPEPTIDES | 2014 |
|
RU2674604C2 |
Authors
Dates
2005-08-27—Published
2000-06-27—Filed